CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $11.88M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 4.54: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
406.73MUSDvs all stocks (USD)
Revenue (TTM)
11.88MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
11.74%vs all stocks
Market Capitalization
406.73MUSDvs all stocks (USD)
Enterprise Value
318.47MUSDvs all stocks (USD)
Forward P/E
-5.08xvs Biotechnology peers
Price to Sales (TTM)
35.06xvs Biotechnology peers
Price to Book (MRQ)
2.79xvs Biotechnology peers
Enterprise to Revenue
26.80xvs Biotechnology peers
Enterprise to EBITDA
-2.13xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-2380.08%vs Biotechnology peers
Return on Assets (TTM)
-64.06%vs Biotechnology peers
Return on Equity (TTM)
-75.83%vs Biotechnology peers
Revenue (TTM)
11.88MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.5900USDUpdated Jul 18, 2026Quarterly Revenue Growth
-90.42%vs Biotechnology peers
Gross Profit (TTM)
11.88MUSDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-162.08MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-69.62MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-153.94MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
10.84MUSDFY2025 · Dec 31, 2025Operating Income
-152.63MUSDvs all stocks (USD)
Pre-tax Income
-151.94MUSDFY2025 · Dec 31, 2025Income Tax Expense
2.00MUSDFY2025 · Dec 31, 2025Net Income
-153.94MUSDFY2025 · Dec 31, 2025EBIT
-149.76MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-149.67MUSDFY2025 · Dec 31, 2025Research & Development
138.09MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
25.39MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.88MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.19MUSDFY2025 · Dec 31, 2025EPS (Basic)
-12.81USDFY2025 · Dec 31, 2025EPS (Diluted)
-12.81USDFY2025 · Dec 31, 2025Basic Shares Outstanding
10.41MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
10.41MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-153.94MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-64.80MUSDFY2025 · Dec 31, 2025Free Cash Flow
-65.72MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
213.30MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-153.94MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
84.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
13.30MUSDFY2025 · Dec 31, 2025Other Non-cash Items
82.40MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-18.00MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.08MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
9.28MUSDFY2025 · Dec 31, 2025Capital Expenditures
-919.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-72.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-919.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
-177.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
1.27MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
322.98MUSDFY2025 · Dec 31, 2025Shares Outstanding
27.57MSharesUpdated Jul 18, 2026Float Shares
14.10MSharesUpdated Jul 18, 2026Shares Short
3.67MSharesUpdated Jul 18, 2026Short Ratio
10.07daysvs all stocks
Short % of Shares Outstanding
30.43%vs all stocks
% Held by Insiders
0.57%vs all stocks
% Held by Institutions
96.69%vs all stocks
Total Cash (MRQ)
189.16MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.69USDUpdated Jul 18, 2026Total Debt (MRQ)
1.54MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0084xvs Biotechnology peers
Current Ratio (MRQ)
13.78xvs Biotechnology peers
Book Value per Share (MRQ)
5.41USDUpdated Jul 18, 2026Total Assets
240.29MUSDvs all stocks (USD)
Total Current Assets
236.66MUSDFY2025 · Dec 31, 2025Total Liabilities
37.28MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.64MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.21MUSDFY2025 · Dec 31, 2025Total Current Liabilities
36.07MUSDFY2025 · Dec 31, 2025Cash
213.19MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
213.19MUSDFY2025 · Dec 31, 2025Accounts Receivable
18.00MUSDFY2025 · Dec 31, 2025Accounts Payable
10.00MUSDFY2025 · Dec 31, 2025Short-term Debt
435.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
4.16MUSDFY2025 · Dec 31, 2025Other Current Liabilities
5.00MUSDFY2025 · Dec 31, 2025Long-term Debt
1.21MUSDFY2025 · Dec 31, 2025Common Stock (Book)
28.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-171.81MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
203.01MUSDvs all stocks (USD)
52-Week Low
8.72USDUpdated Jul 18, 202652-Week High
27.41USDUpdated Jul 18, 202652-Week Change
11.74%vs all stocks
50-Day MA
18.22USDUpdated Jul 18, 2026200-Day MA
14.64USDUpdated Jul 18, 2026Avg 10-Day Volume
461.71KSharesUpdated Jul 18, 2026Avg 30-Day Volume
386.64KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-5.88USDUpdated Jul 18, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 35.06Revenue Growth YoY: -0.90
Financial Health
Altman Z-Score 4.54: safe zoneNotable
Altman Z-Score: 4.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $11.88M, lower than 95% of all stocks globallySignificant
Revenue (USD): 11,883,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Kamada Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Century Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
C4 Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aarti Drugs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Zhenghai Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Novartis India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Larimar Therapeutics Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
First Hi-tec Enterprise Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Paramita Bangun Sarana Tbk
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated